Inozyme Pharma Inc's ROI from its first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Inozyme Pharma Inc's ROI in the first quarter of 2025?
Inozyme Pharma Inc recorded a cumulative net loss of $-107 million during 12 months ending in the first quarter of 2025, resulting in a negative return on investment (ROI) of -99.8%.

Within the Healthcare sector 732 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Mar 31 2025 quarter, so far to 4261, from total ROI ranking in the fourth quarter of 2024 at 4767.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Investment Change TTM	-37.38 %	-16.64 %	6.19 %	28.28 %	25.09 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	52	104	131	140	165
Return On Investment (TTM)	-99.8 %	-75.59 %	-62.03 %	-51.77 %	-45.16 %
INZY's Overall Ranking	# 4261	# 4767	# 4151	# 4068	# 4040
Seq. Investment Change TTM	-20.77 %	-13.24 %	-9.07 %	0.19 %	5.45 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-107	-102	-96	-89	-77

INZY Company Profile >> Back to INZY Roi Comparisons >> See Annual INZY Return On Investment

Return On Investment INZY's Ranking
Within:	No.
Industry	# 340
Sector	# 733
Overall	# 4261

Return On Investment Statistics
High	Average	Low
-33.69 %	-52.75 %	-99.8 %
(Sep 30 2021)		(Mar 31 2025)

Financial Statements
Inozyme Pharma Inc's I. Quarter Investments	$ 52 Millions	INZY's Balance sheet
Inozyme Pharma Inc's I. Quarter Income	$ -28 Millions	Quarterly INZY's Income Statement
INZY's Income by Division		See INZY's Income by Division

INZY Annual Return On Investment	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Investments in Millions	89	186	124	112	159
Y / Y Investment Growth	-52.04 %	49.55 %	11.23 %	-29.79 %	-
Net Income in Millions	-102	-71	-67	-57	-56
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-114.27 %	-38.23 %	-53.87 %	-50.6 %	-35.4 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
INZY's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for INZY's Competitors
Subscribers only: Roi for Inozyme Pharma Inc's Suppliers
Subscribers only: Return On Investment for INZY's Customers

Other Ratios
INZY's Roa	INZY's Inventory Turnover Ratio	INZY's Growth Rates	INZY's Dividend Statistics
	INZY's Profitability Ratios	INZY's Asset Turnover Ratio	INZY's Dividend Growth
INZY's Roe	INZY's Valuation Ratios	INZY's Financial Strength Ratios	INZY's Dividend Payout Ratio

Companies with similar Return On Investment at Mar 31 2025, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:38:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.